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Objectives: Comparison of synthetic hydroxyapatite/silica oxide, xenogenic 
hydroxyapatite based bone substitute materials with empty control sites in terms of 
bone regeneration enhancement in a rabbit calvarial 4 non-critical sized defect 
model. 
Methods: In each of six rabbits, four bicortical calvarial bone defects were 
generated. The following four treatment modalities were randomly allocated: (1) 
empty control site, (2) synthetic hydroxyapatite/silica oxide based (HA/SiO) test 
granules, (3) xenogenic hydroxyapatite based granules, (4) synthetic 
hydroxyapatite/silica oxide based (HA/SiO) test 2 granules. The results of the latter 
granules have not been reported due to their size being 3 times bigger than the other 
two granule types. After four weeks, the animals were sacrificed and un-decalcified 
sections were obtained for histological analyses.  
For statistical analysis the Kruskan-Wallis test was applied (p<0.05). 
Results: Histomorphometric analysis showed an average area fraction of newly 
formed bone of 12.32±10.36% for the empty control, 17.47±6.42% for the xenogenic 
hydroxyapatite based granules group, and 21.20±5.32% for the group treated with 
synthetic hydroxyapatite/silica oxide based granules. Based on the middle section, 
newly formed bone bridged the defect to 38.33±37.55% in the empty control group, 
54.33±22.12% in the xenogenic hydroxyapatite based granules group, and to 
79.00±13.31% in the synthetic hydroxyapatite/silica oxide based granules group. The 
bone to bone substitute contact was 46.38±18.98% for the xenogenic and 
59.86±14.92% for the synthetic hydroxyapatite/silica oxide based granules group. 
No significant difference in terms of bone formation and defect bridging could be 
detected between the two bone substitute materials or the empty defect. 
Conclusion: There is evidence that the synthetic hydroxyapatite/silica oxide 
granules provide comparable results to a standard xenogenic bovine mineral in terms 
of bone formation and defect bridging in non critical size defects.  
 
The substitution of autologous bone with synthetic materials to treat bone defects 
represents still a challenge. Hydrated calcium phosphates, as hydroxyapatite, are 
often used to develop synthetic bone substitutes due to their crystallographic 
structures similar to bone (Hing et al. 2006). For extended bone defects autologous 
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bone is still the gold standard since hydroxyapatite based scaffolds need additions 
like stem cells (Cancedda et al. 2007) and/or growth factors (Warnke et al. 2006) to 
compete with them. For smaller defects, however, hydroxyapatite based scaffolds 
improved by the addition of inorganic substances like silicon or by the application of 
more sophisticated handling procedures omitting sintering yielding in a reduced 
osteoconductivity (Henkel et al. 2006) might also serve the purpose.    
In 1970 Carlisle (Carlisle 1970) found out that deficiency in silicon lead to abnormal 
bone formation. Based on several other studies confirming this initial findings 
(Schwarz & Milne 1972, Seaborn & Nielsen 2002), silicon has become an important 
research topic in bone metabolism. Silicon is a major element in bioactive glass and 
contributes to its enhanced bioactivity in vitro (Gao et al. 2001 , Gough et al. 2004) 
with significant up-regulation of osteoblast proliferation and gene expression when 
exposed to ionic dissolution products of bioactive glasses (Gao 2001, Hing et al. 
2006, Xynos, et al. 2001).  
In 2000, mimicking the postmenopausal state, Rico and co-workers (Rico et al. 2000) 
detected in ovariectomized rats, that very high level of dietary silicon may abolish 
bone mineral loss by increasing bone mineral content. A similar finding was stated in 
2004 by Jugdaohsingh and co-workers (Jugdaohsingh et al. 2004) which suggested 
in their Framingham Offspring Cohort study that higher dietary silicon intake in men 
and younger women may have salutary effects on skeletal bone health, especially 
cortical bone health.  
In the course of the development of synthetic bone substitution materials many 
researchers up to date have demonstrated in preclinical tests the benefits to early 
bone ingrowth and repair through incorporation of silicon into porous HA (Hing et al. 
2006, Patel et al. 2005, Seaborn & Nielsen 2002) or into calcium silicate ceramics 
(Xu et al. 2008). Others confirmed the influence of silicon on cell proliferation ability 
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when compared to phase pure HA (Xu & Khor 2007) in vitro. In a recent paper Huang 
and co-workers (Huang et al. 2008) showed that internalization of mesoporous silica 
nanoparticles induced a significant but transient osteogenic signal in human 
mesenchymal stem cells.  
During their synthesis process, most bone substitutes are sintered resulting in more 
compact and less porous materials, where osteoconductivity might be reduced 
(Gerike et al. 2006). The present test material is a non-sintered nano-crystalline 
hydroxyapatite embedded in a highly porous silica gel matrix (HA/SiO). In order to 
guarantee both high osteoinductive property and biodegradability, the granules are 
loosely packed and present porosity between 60-80% (Werner et al. 2002). The gold 
standard bone substitute material is a deproteinized bovine bone mineral (DBBM), 
consisting of a mineral osseous matrix where the organic components have been 
removed by pyrolysis (Spector 1994), a procedure which also sinters the material.  
Clinical outcomes of diverse procedures using DBBM are very well documented 
(Esposito et al. 2006, McAllister & Haghighat 2007). Randomized clinical trials with 
the synthetic non-sintered HA/SiO bone substitute material are not available yet but 
several studies have been published recently. An immunohistochemical study on 
biopsies from human jaws treated with the synthetic non-sintered HA/SiO bone 
substitute material indicates that this material has osteoconductive and biomimetic 
properties and is integrated into the host’s physiological bone turnover as early as 
3.5 month postoperatively (Götz et al. 2008). A 3-year clinical and radiographic case 
study on 13 patients showed successful outcome of implants placed in conjunction 
with maxillary sinus floor augmentation using this synthetic hydroxyapatite/silica 
oxide based material (Heinemann et al. 2009). Another preliminary histological study 
with the same material shows sufficient bone formation in specimens harvested 6 
months after sinus lifts were performed in severely resorbed maxillae (Canullo & 
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Dellavia 2009). In essence all the results published so far look promising but more 
information in particular comparing this material to the gold standard material are 
needed for the formulation of application specific recommendations for the 
practitioner. 
The aim of this study was to compare bone regeneration in non critical size calvarial 
defects of rabbits treated with the gold standard DBBM, the non-sintered HA/SiO or 
left untreated to directly compare the performance between the gold standard bone 
substitute and the newly developed material in vivo.  
 
 
Material and methods 
 
Bone substitute materials 
Bone substitute materials of comparable size were used. The synthetic 
hydroxyapatite/silica oxide based granules are produced by Artoss (Rostock, 
Germany) and distributed as Nanobone® granules of 0.25-1 mm in diameter. 
NanoBone® is a fully synthetic bone graft substitute in granulate form. It consists of 
nanocrystalline hydroxyapatite (76 weight per cent) and silica (24 weight per cent). 
This bioceramic is produced using a modified technique at 200°C. Material porosity 
exceeds 80%, with pore sizes ranging from some nanometers to some 100 microns 
(Dietze et al. 2006). Xenogenic hydroxyapatite particles are produced by Geistlich 
Biomaterials (Wolhusen, Switzerland) and distributed as BioOss® granules of 0.25-1 
mm in diameter. This natural product is deproteinized and sintered at 1100 °C. 
Material porosity is between 70 and 75%, with pore sizes from several nanometers to 




Rabbits were sedated with 80mg/kg Ketamin (Narketan® 10 ad us. vet., 
Injektionslösung, Ketamin 100mg/ml, Vetoquinol AG Ittigen, Bern Schweiz and  
Xylazin 2mg/kg s.c  (Rompun® 2% ad us. vet., Injektionslösung, Bayer Health Care 
Distribution  Provet AG, Lyssach Schweiz.(Xylazinum 20mg(ml).  Inhalation with 
Isofluran was mainainted at 2%-2.5% (Attane, Isoflurane ad us vet. MINRAD INC, 
Buffalo, NY, USA, Distribution, Provet AG, Lyssach Schweiz). The flow rate for 
oxygen was 0.3 l/min and for NO2 0.2 l/min.  
The surgical area was clipped and prepared with iodine for aseptic surgery.  A linear 
incision was made from the nasal bone to the midsagittal crest. After the deflection of 
the soft tissues, a subperiosteal dissection of the operation site was performed 
(occipital, frontal, and parietal bones). Four 6 mm craniotomy defects were created (2 
in the parietal and 2 in the frontal bone) with a 6 mm trephine bur using a dental hand 
piece (Jung, et al. 2005). The surgical area was rinsed with saline to remove bone 
debris. To avoid any dural perforation, the defects marked half way through the bone 
by the trephine bur were finalized by a round bur creating a 6 mm defect. The use of 
a round bur preserves the dura mater, which is strong enough to prevent a prolapse 
of brain tissue into 6 mm defects in the rabbit calvarium. In each animal, one 
untreated defect was compared to one defect treated with BioOss, and one treated 
with Nanobone®. The forth defect was filled with another bone substitute of non-
sintered nanocrystalline hydroxyapatite which was not included in this study report, 
since the size of these particles was much bigger than that of the other 2 bone 
substitutes (Fig 1). Prior to application both materials were wetted by a physiological 
saline solution to improve their ease of handling. Dependent on the thickness of the 
calvarial bone 0.075 - 0.10 g of bone substitute were placed in the defect so that the 
entire defect was filled and contoured like the original calvarial bone. After placement 
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of the materials, the soft tissues were closed with sutures. Analgesia was provided 
with a Transdermal patch (Durogesic® Matrix JANSSEN-CILAG AG, Baar 
Switzerland: Durogesic Matrix 25 µg/h: 4.2 mg Fentanyl per patch 10.5 cm²; 72 
hours). At 4 weeks the rabbits were sedated with Ketamin/Xylazin s.c, euthanized by 
an injection of Pentobarbital 120mg/kg i.v. or i.cardial (Esconarkon ad us vet. 
Pentobarbitalum natricum 200mg; Streuli Pharma SA Uznach, Switzerland), and the 
calvarial bones were excised. 
 
Radiographical and histological analyses  
Specimens were x-rayed using a dental radiographical unit with ultra speed dental 
films (Eastman Kodak Company, NY, USA). The radiographs were photographed, 
scanned and later used to localize the middle section of the defects. After 
radiography, the samples were first prepared with a sequential water substitution 
process which involved 48 hr in 40% ethanol, 72 hr in 70% ethanol (changed 24 hr), 
72 hr in 96% ethanol and finally 72 hr in 100% ethanol.  Samples were placed in 
xylene for 72 hr for defatting of the recovered bone (changed every 24 hr). Next, 
infiltration was performed by placing the samples in methyl methacrylate (MMA) for 
72 hr (Fluka 64200) followed by three days in 100 ml MMA + 2 g di-benzoylperoxid 
(Fluka 38581), at 4 Co. Samples were embedded by placing them in 100 ml MMA + 3 
g di-benzoylperoxid + 10 ml plastoid N or dibuthylphtalat (Merck 800 19.25) and 
allowing polymerization to occur at 37 Co in a air tight water bath. 4.5 µm sections 
were prepared from the middle of the defects and stained with Goldner Trichrome 






In order to determine which percentage of the defect was already bridged by bone, 
the areas of the middle section with bone tissue were projected onto the x-axis, and 
the stretches where bone formation had occurred were summed up. Bone bridging is 
given in percentage of the defect width (6 mm).  
 
Histomorphometry 
Quantitative evaluation of bone regeneration was assessed by applying standard 
histomorphometric techniques. Measurements were carried out on a picture mosaic 
taken from the entire area of interest via a light microscope at a magnification of 
160x, using a superimposed test grid of points and cycloid lines. The numbers of test 
points overlying the profiles of the different components (i.e. mineralized bone tissue, 
non-mineralized tissue and graft particles) were counted. Test points are defined and 
symbolized according to the standard nomenclature of the International Society for 
Stereology (Exner 1987) The graft to bone contact was calculated by the number of 
intersections between graft particles and the outlines of either mineralized bone or 
non-mineralized tissue.  
 
Statistical Analysis  
The primary unit of analysis was the animal. Mean values and standard deviations 
were calculated for the amount of bone formation, for bone bridging and for bone to 
bone substitute contact in the middle section within the original defect. The 
significance of differences was evaluated by the Friedman-test. Statistical analysis 







During operation the different bone substitute materials could be applied easily 
especially after they had been wetted by a physiological saline solution (Figure 1). 
After operation no adverse reaction occurred. All the animals remained in good 
health.  
The microscopic examination confirmed the lack of any adverse effects which could 
have been induced by the different bone substitutes. New bone formation mainly 
originated from the bony defect borders directed toward the centre of the defect. 
Complete bridging of the former defects with mineralized bone occurred in 1 of the 
samples treated with synthetic hydroxyapatite/silica oxide based granules (Fig. 2F). 
Solid cortical bone developed around the xenogenic hydroxyapatite particles (Fig. 
2C,D) and the synthetic hydroxyapatite/silica oxide based particles (Fig. 2E,F). The 
solid appearance of the newly formed bone covering the bone substitutes was 
evident in both bone substitute groups at higher magnifications (Fig.2a-e).  
Histomorphometry 
Histomorphometric analyses of all defect sites have been performed on Goldner-
Trichrome-stained middle sections. The histomorphometric results on newly formed 
bone tissue in the defect are 12.32±10.36% for the empty control, 17.47±6.42% for 
the DBBM group, and 21.20±5.32% for the group treated with synthetic HA/SiO 
based granules (Fig. 3). No significant differences between the 3 treatment 






Based on Goldner-Trichrome-stained middle sections newly formed bone bridged the 
defect to 38.33±37.55% in the empty control group, 54.33±22.12% in the DBBM 
granules group, and to 79.00±13.31% in the synthetic hydroxyapatite/silica oxide 
based granules group (Fig. 4). Bone bridging was not significantly different between 
these groups. 
 
Bone to bone substitute contact 
The results on bone to bone substitute contact were determined 
histomorphometrically by using randomly distributed cycloids distributed all over the 
middle section of the original defect. From all cycloids crossing the bone substitute 
border 46.38±18.98% entered immediately into bone tissue for the xenogenic and 
59.86±14.92% for the synthetic hydroxyapatite/silica oxide based granules group. 
However, the elevated bone to bone substitute contact in the synthetic compared to 




For the here presented animal study about a synthetic hydroxyapatite/silica oxide 
based bone substitution material the calvarial defect model was chosen because of 
1) the poor blood supply; 2) the lack of muscles and minuscule amount of bone 
marrow as potential source for stem cells; 3) and the bone quality which is 
characteristic of cranio-maxillofacial bones. All together this makes it a relevant and 
demanding model to test bone substitute materials (Schmitz & Hollinger 1986) also 
for dental use (Jung et al. 2005). Since this model allows the creation of 4 non-critical 
size defects, 4 treatment modalities can be compared in a single animal, thus 
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minimizing the number of animals needed. Due to the short healing period of 1 
month, bone formation in the empty control is still progressing and the defect has not 
healed. Therefore these results are comparable with 1 month results in critical size 
defects where bone formation ceases after 24 weeks even if the defect has not 
healed (Honma et al. 2008).  
The overall results suggest that in all categories evaluated the synthetic HA/SiO 
based bone substitute material performed best, followed by the xenogenic 
hydroxyapatite, and the untreated defect. However, there were no significant 
differences between the two bone substitutes or the empty defect in bone formation 
(Fig. 3), bone bridging (Fig. 4) or bone to bone substitute contact (Fig 5). However, 
for all tested parameters, the average results for the HA/SiO group were always the 
highest.  
The positive effect on bone formation in the HA/SiO group could at least partly derive 
from the presence of silica oxide in the initial phase, the exposure of natural 
hydroxyapatite nanoparticles, and the increased surface area achieved by omitting 
sintering during the production phase.  
A positive effect of silica in the initial phase of bone regeneration has been found in 
other studies as well (Hing et al. 2006, Patel et al. 2005, Xu et al. 2004, Xu & Khor 
2007, Xu et al. 2008). This positive effect can also be claimed by the here tested 
HA/SiO based material, since the nano-sized HA particles are embedded in a silica 
oxide gel phase (Gerike et al. 2006) and almost fully degrade over 8 months (Henkel 
et al. 2005, Henkel et al. 2006). Another type of hydroxyapatite based materials aim 
to use the positive effect of silica by silica oxide doping. For silica doped 
hydroxyapatite a positive effect on bone regeneration was claimed (Hing et al. 2006, 
Patel et al. 2005) although the bioavailability and effective silica concentrations might 
be too low for a biological response (Bohner 2009). Further analysis of the 
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degradation and the release profile of ions from the HA/SiO material as well as 
effects of released ions on bone forming cells are needed to fully understand the 
biological effect of the HA/SiO material on bone regeneration. 
Degradation of the silica oxide gel over time will lead to the exposure of the nano-
sized hydroxyapatite particles to the cells present in the bone defect. From other 
studies it is known that HA nanoparticles have a positive effect on bone formation 
(Liu et al. 2009) by promoting the osteogenic differentiation of mesenchymal stem 
cells. In the same study it was also shown that this positive effect is dependent on the 
concentration of HA nanoparticles and that an overload of particles has even an 
adverse effect on the osteogenic differentiation of mesenchymal stem cells (Liu et al. 
2009). Therefore just the presence of HA nanoparticles in bone substitute materials is 
not sufficient to guarantee a positive biological effect.    
Another interesting aspect of the HA/SiO based material during degradation is the 
substitution of the SiO2 gel phase by a proteinaceous organic matrix consisting of 
alkaline phosphatase, collagen I and also growth factors like bone morphogenetic 
protein-2 (Götz et al. 2008). This substitution was found in human biopsies with 
healing times between 3.5 and 12 months. The study we performed reports on one 
month results, where this exchange was just beginning and might not affect the 
outcome of our experiment. Of more relevance in the short term might be the surface 
of the materials and the existence of micro and macropores. Most of the synthetic 
hydroxyapatite based materials are sintered during the production phase leading to 
specific surfaces of below 2 m2 /g, reduced micropores (Weibrich et al. 2000) and 
osteoconductivity (Henkel et al. 2006). The xenogenic and osteogenic DBBM exhibits 
a surface area of 79.7 m2 /g (Weibrich et al. 2000) which is well in the range of 
synthetic HA/SiO with a surface area of 84.0 m2 /g (Götz et al. 2008) and could be 
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the reason why both materials show no significant difference in defect bone bridging, 




There is evidence that the synthetic hydroxyapatite/silica oxide granules provide 
comparable results to a standard xenogenic bovine mineral in terms of bone 
formation and defect bridging in non critical size defects.  
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Fig. 1. Picture of the operative site showing one example for defects before and after 
application of bone substitute materials. A: empty, B:  sintered bovine bone mineral 
(DBBM) (0.25-1mm), C: Synthetic hydroxyapatite/silica oxide granules (HA/SiO) 
(0.25-1mm) D: Synthetic hydroxyapatite/silica oxide granules (1-3 mm) Please note 
that the size of the material (D) was much bigger than that of the other materials. 
Therefore these results are not reported here. 
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Fig. 2. Histological sections of the cranial defects in rabbits 4 weeks postoperatively: 
(A,B) No filling (empty)  as a negative control,  (C,D) xenogenic bone mineral as a 
golden standard,  (E,F)  as test material. Scale in millimeters. Original magnifications 
were 100 fold. Histological sections of the cranial defects in higher magnifications: (a, 
b) sintered bovine bone mineral, (c, d, e) synthetic hydroxyapatite/silica oxide 
granules; scales provided are 100 µm. Original magnifications were 300 fold. The 
areas shown with higher magnification are indicated. 
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Fig. 3. Bone tissue within the defect. The lines to the right of the values indicate the 





Fig. 4. Bony bridging is the percentage of the defect where new bone formation has 
occurred. The lines to the right of the values indicate the median of the group. No 





Fig. 5. Bone to bone substitute contact. The results of the histomorphometric analysis 
revealed no significant difference between the percentages of bone/bone substitute 
interface. The lines to the right of the values indicate the median of the group.   
